T1	PrimaryOutcome 976 1022	proportion of patients in categories 5, 6 or 7
T2	TimeFrame 1023 1045	at day 15 of the study
R1	MeasuredAt Arg1:T1 Arg2:T2	
T3	OutcomeDefinition 524 946	clinical status was recorded using the seven-category ordinal COVID-19 scale: 1, not hospitalized, no limitations on activities; 2, not hospitalized, limitation on activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, on non-invasive ventilation or high flow oxygen devices; 6, hospitalized, on invasive mechanical ventilation or ECMO and 7, death
R2	DefinedAs Arg1:T1 Arg2:T3	
T4	SecondaryOutcome 1075 1131	time to improvement of one category on the ordinal scale
T5	SecondaryOutcome 1133 1165	mean change in the ordinal scale
T6	TimeFrame 1166 1210	from baseline to days 3, 5, 8, 11, 15 and 29
T7	SecondaryOutcome 1212 1258	proportion of patients in categories 5, 6 or 7
T8	TimeFrame 1259 1268	at day 29
T9	SecondaryOutcome 1270 1279	mortality
T10	TimeFrame 1280 1297	at days 15 and 29
T11	SecondaryOutcome 1299 1324	duration of hospital stay
T12	SecondaryOutcome 1326 1375	number of days alive and free from oxygen support
T13	SecondaryOutcome 1377 1435	number of days alive and free from mechanical ventilation.
T14	OtherOutcome 1759 1786	Serious adverse events (AE)
T15	OtherOutcome 1788 1803	grade 3 or 4 AE
T16	OtherOutcome 1808 1827	infusion related AE
T17	TimeFrame 1829 1865	within 24 hours after administration
R4	MeasuredAt Arg1:T16 Arg2:T17	
R5	MeasuredAt Arg1:T7 Arg2:T8	
R6	MeasuredAt Arg1:T9 Arg2:T10	
R7	MeasuredAt Arg1:T5 Arg2:T6	
T18	TimeFrame 1501 1531	at days 3, 5, 8, 11, 15 and 29
T19	OtherOutcome 1436 1485	Serial naso/oropharyngeal swabs and blood samples
R3	MeasuredAt Arg1:T19 Arg2:T18	
